Vasorelaxing Effects of Estetrol in Rat Arteries

Total Page:16

File Type:pdf, Size:1020Kb

Vasorelaxing Effects of Estetrol in Rat Arteries 97 Vasorelaxing effects of estetrol in rat arteries Rob H P Hilgers, Suzanne Oparil, Wout Wouters1 and Herjan J T Coelingh Bennink1 Division of Cardiovascular Disease, Department of Medicine, Vascular Biology and Hypertension Program, University of Alabama at Birmingham, 1034 Zeigler Research Building, 703 19th Street South, Birmingham, Alabama 35294-0007, USA 1Pantarhei Bioscience, Zeist, The Netherlands (Correspondence should be addressed to S Oparil; Email: [email protected]) Abstract This study compared ex vivo relaxing responses to the hyperpolarization did not alter relaxation to either E4 or E2 naturally occurring human hormone estetrol (E4)vs in uterine arteries. Combined blockade of NO release and 17b-estradiol (E2) in eight different vascular beds. Arteries action with L-NAME and the soluble guanylate cyclase were mounted in a myograph, contracted with either (sGC) inhibitor ODQ resulted in greater inhibition of the phenylephrine or serotonin, and cumulative concentration- relaxation response to E4 compared with E2 in uterine response curves (CRCs) to E4 and E2 (0.1–100 mmol/l) were arteries. Endothelium denudation inhibited responses to both constructed. In all arteries tested, E4 had lower potency than E4 and E2, while E4 and E2 concentration-dependently 2C C E2, although the differential effect was less in larger than blocked smooth muscle cell Ca entry in K -depolarized 2C smaller arteries. In uterine arteries, the nonselective estrogen and Ca -depleted uterine arteries. In conclusion, E4 relaxes receptor (ER) blocker ICI 182 780 (1 mmol/l) caused a precontracted rat arteries in an artery-specific fashion. significant rightward shift in the CRC to both E4 and E2, In uterine arteries, E4-induced relaxations are partially indicating that the relaxation responses were ER dependent. mediated via an endothelium-dependent mechanism invol- C Pharmacological blockade of nitric oxide (NO) synthases ving ERs, sGC, and inhibition of smooth muscle cell Ca2 u by N -nitro-L-arginine methyl ester (L-NAME) blunted entry, but not NO synthases or endothelium-dependent E2-mediated but not E4-mediated relaxing responses, while hyperpolarization. inhibition of prostaglandins and endothelium-dependent Journal of Endocrinology (2012) 215, 97–106 Introduction not bind to SHBG (Hammond et al. 2008). As a result of these favorable metabolic and protein binding properties, The hormone estetrol (estra-1,3,5(10)-trien-3,15a- E4 has excellent oral potency despite its low-to-moderate 16a,17b-tetrol or E4) was discovered in 1965 (Hagen et al. affinity for ERs. 1965). E4 is produced in nature from 17b-estradiol (E2) E4 has been studied in many validated models and has been and estrol (E3) only by the human fetal liver during pregnancy shown to behave as a full ER agonist, similar to E2, in most of via 15a- and 16a-hydroxylase (Schwers et al. 1965, Gurpide these (Coelingh Bennink et al. 2008b, Heegaard et al. 2008, et al. 1966). The concentration of E4 increases during Holinka et al. 2008, Visser & Coelingh Bennink 2009). pregnancy in both the fetus and the mother, but 24 h after However, important differences between E4 and E2 were delivery, the level is undetectable. noted. E4 did not induce synthesis of SHBG in vitro as did E2 The chemical structure of E4 is closely related to that of E2, (Hammond et al. 2008). Recent studies showed that E4 but the pharmacokinetic, metabolic, and endocrinological behaved as an ER antagonist in in vitro and in vivo models of profile of E4 is substantially different from that of E2.E2 has estrogen-dependent breast tumors in the presence of E2.E2 high affinity for the estrogen receptor a (ERa) and ERb behaved as full agonist in these models (Coelingh Bennink (Ki values: 0.2 and 0.05 nmol/l respectively), while E4 has et al. 2008c). E4 is now undergoing clinical testing as the low-to-moderate affinity for ERa and ERb (Ki values: 4.9 estrogenic component of a combined oral contraceptive and and 19 nmol/l respectively; Coelingh Bennink et al. 2008a). for its effects on breast tumors. E2 has very low oral availability because over 99% of an oral The physiological function of E4 is not completely dose is converted into estrone (E1) and E1 sulfate. Most of the understood, although a role in regulating uterine blood circulating E2 is bound to either albumin or sex hormone flow has been suggested. Unilateral intrauterine injection of binding globulin (SHBG), further decreasing plasma levels E4 in nonpregnant oophorectomized ewes has been shown to of free E2 by a factor of about 30. By contrast, E4 does not increase uterine blood flow, although with a 15- to 30-fold undergo phase I metabolism by human HepG2 cells and does lower potency than E3 (Levine et al. 1984). Similarly, Journal of Endocrinology (2012) 215, 97–106 DOI: 10.1530/JOE-12-0009 0022–0795/12/0215–097 q 2012 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org Downloaded from Bioscientifica.com at 09/27/2021 03:01:35PM via free access 98 R H P HILGERS and others . Vasodilator effects of estetrol administration of E2 to ovariectomized ewes results in a rapid both uterine horns were cleared of adipose and connective uterine vasodilation leading to a rise in uterine blood flow tissues. The thoracic aorta and left common carotid artery were within 30–45 min (Killam et al. 1973). This rise in uterine cleaned of connective tissue and cut into 2.5–3 mm segments. blood flow is partially mediated via the release of nitric oxide A fourth-order branch segment of the superior mesenteric (NO) and resultant increases in cGMP secretion, as artery was dissected from the mesentery; a small (200–300 mm shown by local infusion of the NO synthase blocker in diameter) pulmonary arterial segment was dissected from u N -nitro-L-arginine methyl ester (L-NAME; Van Buren the lung; a segment of the left main renal artery was dissected, et al. 1992, Rosenfeld et al. 1996). The dilating effect of E2 and a segment of the middle cerebral artery was dissected from on ovine uterine arteries is ER dependent, as shown by local the brain. The atria and the left ventricle were removed to infusion of the nonselective ER blocker ICI 182 780 in expose the interventricular septum of the heart, and a segment nonpregnant ewes (Magness et al. 2005). of the septal coronary artery was dissected. Aortic and carotid To further profile E4, this study was designed to study the artery segments were mounted between two stainless steel pins, in vitro vasorelaxing effects of E4 and to compare them with whereas the other segments (all 2 mm long) were mounted those of E2. The objectives of this study were 1) to determine between two stainless steel jaws connected with two wires the ex vivo relaxing effects of E4 compared to E2 in rat uterine, (40 mm in diameter) through the lumen of the segment in a thoracic aortic, carotid, mesenteric, pulmonary, renal, middle myograph chamber (Danish Myo Technology, Inc., Aarhus, cerebral, and septal coronary arterial segments; 2) to assess the Denmark) filled with 5 ml KRB solution, maintained at 37 8C, involvement of ERs in the vasorelaxing response to E4 in and continuously aerated with 95% O2 and 5% CO2. Four uterine arteries; and 3) to assess the endothelium-dependent arterial segments were analyzed in parallel. The remaining and endothelium-independent vasorelaxing effects of E4 in segments were temporarily stored at 4 8C. uterine arteries. The uterine artery was chosen for assessment of the acute vasoactive properties of E4 and for comparison of these to the effects of E2 because the uterine arterial Determination of optimal diameters circulation is known to be highly sensitive to the vasodilator Thoracic aortae and carotid and pulmonary arteries were effects of E2. The uterine arteries are exposed to high passively stretched according to a procedure first described by physiological levels of E2 during the follicular and luteal Mulvany & Halpern (1977). Briefly, the segments were phases of the menstrual cycle and during pregnancy, resulting distended stepwise in 100 mm increments measured with a in major increases in uterine blood flow (Magness 1998). built-in micrometer and the wall tension (N/m) was recorded using data acquisition (Powerlab 8/35, ADInstruments, Materials and Methods Colorado Springs, CO, USA) and recording Software (ChartLab7, Colorado Springs, CO, USA). Thoracic aortic Animals segments and carotid arteries were stretched at wall tension corresponding to a pressure of 90 mmHg, whereas A total of 40 female nulliparous Sprague Dawley rats (age pulmonary arteries were stretched at a wall tension 12 weeks) were obtained from Charles River Breeding corresponding to 40 mmHg. At this passive wall tension, G C Laboratories, maintained at constant humidity (60 5%), segments were contracted with high K KRB (60 mmol/l G temperature (24 1 8C), and light cycle (0600–1800 h), and KCl in KRB solution; replacing equimolar NaCl with KCl), fed a standard rat pellet diet (2016 Teklad Global 16% Protein thus generating active wall tension, which was set to a Rodent Diet (Harlan Laboratories, Teklad Diets, Madison, 100% contraction level. WI, USA) ad libitum. All protocols were approved by the All other arterial segments were progressively and actively Institutional Animal Care and Use Committee at the stretched to the internal diameter at which the largest University of Alabama at Birmingham and were consistent contractile response to 10 mmol/l norepinephrine (NE) with the Guide for the Care and Use of Laboratory Animals C or 60 mmol/l K KRB (middle cerebral arteries) was published by the National Institutes of Health. obtained. This internal diameter was referred to as the optimal diameter and the corresponding active wall tension Vessel preparation was set to a 100% contraction level.
Recommended publications
  • Memorandum Date: June 6, 2014
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M.
    [Show full text]
  • Estetrol: New Perspectives for HRT in Menopause and Breast Cancer
    Graziottin A. Singer C. Kubista E. Visser M. Coelingh Bennink H. Estetrol: new perspectives for HRT in menopause and breast cancer patients V Annual International Congress on Human Reproduction on "Family Reproductive Health", Moscow, Russia, January 18-21, 2011 Estetrol: new perspectives for HRT in menopause and breast cancer patients Alessandra Graziottin *, Christian Singer **, Ernst Kubista **, Monique Visser *** and Herjan J.T. Coelingh Bennink *** * Professor at the University of Florence, Italy – Director, Center of Gynaecology, H San Raffaele Resnati, Milan, Italy ** Akademisches Krankenhaus Wien, Wien, Austria *** Pantarhei Bioscience, Zeist, The Netherlands Estetrol (E 4) is a foetal estrogen, produced by the foetal liver during pregnancy only. It has a selective ERalpha and ERbeta receptor bindin g with preference for ERalpha, with antagonist action. E 4 is present at 9 weeks of gestation, with exponential increase of synthesis and blood levels. At term the foetus produces about 3 mg/day. Elimination half-life is 28 hours. Potential applications in women’s life-span include: contraception, hormone replacement therapy (HRT), specifically for vasomotor symptoms, vulvovaginal atrophy and osteoporosis, and therapy of breast cancer. Preliminary data support its efficacy in the treatment of: hot flushes, with significant reduction; in the maturation of the vaginal mucosa, with significant increase of superficial cells at the cytological evaluation; a dose dependent effect on the endometrium: low doses such as 2 mg of Estetrol/day, sufficient to treat a number of symptoms, do not stimulate the endometrium; a significant protective effect on bone: this growing set of data suggest that E 4 could have a new, significant role in the treatment of menopausal symptoms, with an extraordinary safe profile.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : the Unique Potential of Estetrol
    investor day 2016 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : The unique potential of Estetrol 10 :30 – 11 :45Programme: Mithra’sde la journée strategy 11 :45 – 12 :00 : Q&A 12 :00 – 13 :30 : Drink and lunch with Executive Management 13 :30 – 14 :15 : Focus on Estetrol-based projects 14 :15 – 14 :30 : Coffee break 14 :30 – 15 :15 : Focus on long-acting drugs and Mithra CDMO 15 :15 – 15 :30 : Q&A and wrap-up session 15 :30 – 16 :30 : Drink and networking What is Estetrol ? Interview with Professor J.M. Foidart MD. Member of scientific committee Mithra Professor J.M. Foidart MD. Member of scientific committee Mithra 4 Estrogens in the “pill” a very limited family . Estradiol . Synthetic progestin . Ethinylestradiol Over 95% of oral contraceptives contain ethinylestradiol 6 Synthetic Progestins : a very large family First First Second Third New” COCs generation: generation: generation: progestins: > Norethisterone > Norethynodrel > Norgestrel > Desogestrel > Drospirenone > Norethinodrel > Nortestosterone > Levonorgestrel > Etonogestrel > Dienogest > High doses of derivatives > Gestodene > Trimestone synthetic estrogen >Pregnanes > Nesterone and androgenic > Norgestimate > Nomegestrol Ac. progestin > Promegestone Jan 2014 EMA classification progestins by type . Structural modification: to reduce androgenic side-effects but maintain strong progestational activity . Wider health benefits depending on progestin properties Reviewed in Brynhildsen J. Ther Adv Drug Saf. 2014;5(5):201-13; Benagiano7 G, et al. Eur J Contracept Reprod Health Care. 2004;9(3):182- 93; Sitruk-Ware R. Hum Reprod Update. 2006;12(2):169-78; Micks E, et al. Endocr Connect. 2015;4(4):R81-92 The third and fourth generation progestins and pills are not androgenic.
    [Show full text]
  • The Structural Biology of Oestrogen Metabolism
    Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 27–49 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology jo urnal homepage: www.elsevier.com/locate/jsbmb Review The structural biology of oestrogen metabolism ∗ Mark P. Thomas, Barry V.L. Potter Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK a r t i c l e i n f o a b s t r a c t Article history: Many enzymes catalyse reactions that have an oestrogen as a substrate and/or a product. The reac- Received 11 September 2012 tions catalysed include aromatisation, oxidation, reduction, sulfonation, desulfonation, hydroxylation Received in revised form and methoxylation. The enzymes that catalyse these reactions must all recognise and bind oestrogen but, 10 December 2012 despite this, they have diverse structures. This review looks at each of these enzymes in turn, describing Accepted 12 December 2012 the structure and discussing the mechanism of the catalysed reaction. Since oestrogen has a role in many disease states inhibition of the enzymes of oestrogen metabolism may have an impact on the state or Keywords: progression of the disease and inhibitors of these enzymes are briefly discussed. Oestrogen This article is part of a Special Issue entitled ‘CSR 2013’. Protein structure © 2012 Elsevier Ltd. Open access under CC BY license. Reaction mechanism Aromatase Sulfatase Sulfotransferase 17␤-Hydroxysteroid dehydrogenase Contents 1. Introduction . 27 2. Methods . 29 3. Oestrogen sulfotransferase . 29 4. Steroid sulfatase. 31 5. 17␤-Hydroxysteroid dehydrogenases . 33 6. Aromatase (cytochrome P450 19A1, oestrogen synthase) . 36 7. Enzymes of steroid hydroxylation .
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Estetrol for Menopause Symptoms: the Cinderella of Estrogens Or Just Another Fairy Tale? Nancy King Reame, MSN, Phd, FAAN
    CE: D.C.; MENO-D-20-00177; Total nos of Pages: 3; MENO-D-20-00177 Menopause: The Journal of The North American Menopause Society Vol. 27, No. 8, pp. 000-000 DOI: 10.1097/GME.0000000000001601 ß 2020 by The North American Menopause Society EDITORIAL Estetrol for menopause symptoms: the Cinderella of estrogens or just another fairy tale? Nancy King Reame, MSN, PhD, FAAN espite the advent of lower dosing, transdermal deliv- affinity (<5%) compared to E2.3 Interest was, however, ery, and targeted use in younger age groups, safety renewed in the 2000s when preclinical and pharmacokinetic D concerns persist regarding the potential for estrogen- studies showed that estetrol elicits considerable estrogenic based menopause hormone therapy (MHT) to raise breast effects in rat models for both hot flashes and bone loss, but cancer and thromboembolism risk. In the last few decades a with minimal stimulation of liver and breast.4 More recent wealth of scientific advances has revealed the molecular biol- translational studies5 showed that E4 was bestowed with an ogy of the estrogen receptors (ERs) a and b, opening up new intriguing ER pharmacology, unique from SERMs, thus directions for their pharmaceutical manipulation and promise pushing it to center stage for its potential as the first native to improve hormone therapies. With the help of the ER knock- estrogen with selective action in tissues (NEST). out mouse model, an array of estrogen-mediated actions in Unlike other estrogens, which interact with both a and b tissues throughout the body was elucidated, followed by the receptors at the cell surface and in the nucleus, E4 not only emergence of new compounds with tissue-dependent, ER preferentially binds to the ERa subtype, but does so in a distinct agonistic, antagonistic, and mixed actions.1 Although several non-SERM way.
    [Show full text]
  • Clinical Applications for Estetrol Visser M, Coelingh Bennink HJT J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie Clinical Applications for Estetrol Visser M, Coelingh Bennink HJT J. Reproduktionsmed. Endokrinol 2010; 7 (Sonderheft 1), 56-60 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Clinical Applications for Estetrol # Clinical Applications for Estetrol * M. Visser, H. J. T. Coelingh Bennink In this paper the potential clinical applications for the human fetal estrogen estetrol (E4) are presented based on recently obtained data in preclinical and clinical studies. In the past E4 has been classified as a weak estrogen due to its rather low estrogen receptor affinity. However, recent research has demonstrated that due to its favorable pharmacokinetic properties, especially the slow elimination and long half-life, E4 is an effective orally bioavailable estrogen agonist with estrogen antagonistic effects on the breast in the presence of estradiol.
    [Show full text]
  • Drospirenone and Estetrol
    PATIENT & CAREGIVER EDUCATION Drospirenone and Estetrol This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Nextstellis Brand Names: Canada Nextstellis Warning Smoking cigarettes while using this drug raises the chance of severe heart and blood-related side effects. This chance is raised with age (mainly older than 35 years of age). It is also raised with the number of cigarettes smoked. It is strongly advised not to smoke. What is this drug used for? It is used to prevent pregnancy. If your child has been given this drug for some other reason, talk with the doctor for more information. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. Drospirenone and Estetrol 1/8 If your child has ever had a very bad or life-threatening reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness. If your child has kidney problems. If your child has adrenal gland problems. If your child has had any of these health problems: Blood clots, blood clotting problem, breast cancer or other cancer where hormones make it grow, diseased blood vessels in the brain or heart, heart valve problems, heart disease, a certain type of abnormal heartbeat (atrial fibrillation), chest pain caused by angina, heart attack, stroke, high blood pressure, liver tumor or other liver problems, severe headache or migraine, or diabetes.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,068,830 Diamandis Et Al
    US00606883OA United States Patent (19) 11 Patent Number: 6,068,830 Diamandis et al. (45) Date of Patent: May 30, 2000 54) LOCALIZATION AND THERAPY OF FOREIGN PATENT DOCUMENTS NON-PROSTATIC ENDOCRINE CANCER 0217577 4/1987 European Pat. Off.. WITH AGENTS DIRECTED AGAINST 0453082 10/1991 European Pat. Off.. PROSTATE SPECIFIC ANTIGEN WO 92/O1936 2/1992 European Pat. Off.. WO 93/O1831 2/1993 European Pat. Off.. 75 Inventors: Eleftherios P. Diamandis, Toronto; Russell Redshaw, Nepean, both of OTHER PUBLICATIONS Canada Clinical BioChemistry vol. 27, No. 2, (Yu, He et al), pp. 73 Assignee: Nordion International Inc., Canada 75-79, dated Apr. 27, 1994. Database Biosis BioSciences Information Service, AN 21 Appl. No.: 08/569,206 94:393008 & Journal of Clinical Laboratory Analysis, vol. 8, No. 4, (Yu, He et al), pp. 251-253, dated 1994. 22 PCT Filed: Jul. 14, 1994 Bas. Appl. Histochem, Vol. 33, No. 1, (Papotti, M. et al), 86 PCT No.: PCT/CA94/00392 Pavia pp. 25–29 dated 1989. S371 Date: Apr. 11, 1996 Primary Examiner Yvonne Eyler S 102(e) Date: Apr. 11, 1996 Attorney, Agent, or Firm-Banner & Witcoff, Ltd. 87 PCT Pub. No.: WO95/02424 57 ABSTRACT It was discovered that prostate-specific antigen is produced PCT Pub. Date:Jan. 26, 1995 by non-proStatic endocrine cancers. It was further discov 30 Foreign Application Priority Data ered that non-prostatic endocrine cancers with Steroid recep tors can be stimulated with Steroids to cause them to produce Jul. 14, 1993 GB United Kingdom ................... 93.14623 PSA either initially or at increased levels.
    [Show full text]
  • The Next Generation of Oral Contraception: Advances in Estrogens
    SUPPLEMENT TO FREE CME Credit To receive CME credit, please read the articles and June 2021 go to www.omniaeducation.com/estrogen to access the posttest and evaluation. The Next Generation of Oral CME CREDITS: .25 CREDITS OVERVIEW: Contraception: Advances in This article traces the evolution of estrogen in contraception, with a special focus on the Estrogens concept of native estrogen with specific actions in tissues, or NEST. Research surrounding estetrols Patricia Geraghty, MSN, FNP-BC, WHNP (E4), receptor binding, and target interactions Director of Women’s Health demonstrate that E4 has high selectivity for Comprehensive Wellness the estrogen receptors. Clinical trial data are Walnut Creek, CA presented that support the view that E4 – a high NEST activity estrogen – is a safe and effective Hugh S. Taylor, MD estrogen for use in combined oral contraceptives. Chair, Dept of Obstetrics, Gynecology, and Reproductive Sciences This premise was borne out with the approval Yale School of Medicine of an estetrol/drosperinone combined oral New Haven, CT contraceptive by the US Food and Drug Administration in April 2021. Background REVIEWERS/CONTENT PLANNERS/AUTHORS: There are currently 61 million women of reproductive age (15- • Sean T. Barrett has nothing to disclose. 44 years) in the United States.1 Approximately 43 million (70%) are • Barry A. Fiedel, PhD, has nothing to disclose. • Patricia Geraghty, MSN, FNP-BC, WHNP, receives at risk of unintended pregnancy, meaning that they are sexually consulting fees from AbbVie and Mayne Pharma. active and do not want to become pregnant, but they have the • Amanda Hilferty has nothing to disclose. potential to become pregnant if they and/or their partner(s) fail • Lynne Kolton Schneider, PhD has nothing to to use a contraceptive method correctly and consistently.2 Among disclose.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]